Anti-glomerular basement membrane (GBM) disease manifests as rapidly progressive glomerulonephritis (RPGN) characterized by necrotizing glomerulonephritis (GN) with crescentic proliferation. The non-collagenous domain of the α-3 chain of type IV collagen is identified as the autoantigen, and linear IgG deposition along the GBM aid diagnosis of anti-GBM disease. In rare cases, an association of anti-GBM disease with deposition of immune complexes has been reported. Herein, a case of concurrent anti-GBM nephritis and IgA nephropathy is presented.

CASE REPORT
===========

A 38-year-old Korean woman noticed gross hematuria in April 2016. Laboratory analysis revealed a serum creatinine (Cr) level of 0.65 mg/dL; a serum total protein of 7.9 g/dL; a serum albumin of 4.4 g/dL; a serum anti-GBM antibody of 49 U/mL; a urine spot protein/Cr ratio of 0.360 g/g; and many urine spot erythrocytes. She was recommended further workup and treatment, but she refused. She experienced anorexia and weakness in June 2016. Her serum Cr level was 1.7 mg/dL at the second hospital visit. She was asked for hospitalization, but she refused treatment. She was admitted due to weakness and fever (38.1°C) at the third hospital visit in July 2016. Laboratory analysis at this visit revealed a serum Cr level of 5.45 mg/dL; a serum total protein of 7.5 g/dL; a serum albumin of 3.5 g/dL; a serum antiGBM antibody of 187.2 U/mL; a urine spot protein/Cre ratio of 1.4 g/g; and many urine spot erythrocytes. Serum antinuclear antibody, anti-double stranded DNA, anti-neutrophil cytoplasmic antibody (ANCA), and antibodies to HIV, hepatitis B, and hepatitis C were all negative. There was no evidence of lung involvement based on chest computed tomography and no respiratory symptoms.

A renal biopsy contained 16 glomeruli with five global scleroses, six fibrocellular crescents, and five cellular crescents ([Fig. 1A](#f1-jptm-2019-08-05){ref-type="fig"}). An immunofluorescence study showed linear deposition of IgG along the GBM ([Fig. 1B](#f1-jptm-2019-08-05){ref-type="fig"}) and granular deposition of IgA in mesangial spaces ([Fig. 1C](#f1-jptm-2019-08-05){ref-type="fig"}). Electron microscopy showed a diffusely wrinkled GBM and mesangial electron-dense deposition ([Fig. 1D](#f1-jptm-2019-08-05){ref-type="fig"}).

The pathologic diagnosis was "concurrent anti-GBM crescentic GN and IgA nephropathy," which was treated with intravenous methylprednisolone (500 mg/day for three successive days) with cyclophosphamide (500 mg/day) followed by oral prednisolone (50 mg/day). Plasmapheresis was avoided due to the possibility of side effects. Three months after the treatment, the anti-GBM antibody titer gradually decreased (anti-GBM titer, 15.6 U/mL) and renal function improved (Cr, 2.08 mg/dL) ([Fig. 2](#f2-jptm-2019-08-05){ref-type="fig"}).

This study was approved by the Institutional Review Board of Chungnam National University Hospital with a waiver of informed consent (IRB No. 2016-11-009) and performed in accordance with the 1964 Helsinki declaration and its later amendments.

DISCUSSION
==========

RPGN is classified into three categories as anti-GBM disease, immune complex disease, and ANCA-associated disease. Among these three categories, anti-GBM disease is the rarest and severest form of crescentic GN and is characterized by linear IgG deposition along the GBM with circulating anti-GBM antibodies.1 Overlapping features of crescentic GN are identified as coexistence of anti-GBM disease and ANCA antibodies, or anti-GBM disease and immune complex--mediated GN \[[@b2-jptm-2019-08-05],[@b3-jptm-2019-08-05]\]. ANCA antibodies are detected in 21% to 43% of anti-GBM disease patients and clinical characteristics of dual antibody--positive patients are documented \[[@b3-jptm-2019-08-05],[@b4-jptm-2019-08-05]\]. However, concurrent anti-GBM disease and immune complex--mediated GN is rarely reported and the most frequent form of combined immune complex GN is membranous nephropathy \[[@b2-jptm-2019-08-05]\]. Concurrent anti-GBM disease and IgA nephropathy is rare and clinical characteristics are not well understood.

Herein, a case of concurrent anti-GBM nephritis and IgA nephropathy is presented. A literature review for concurrent antiGBM disease and IgA nephropathy using PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) was performed resulting in identification of a total of nine cases from nine articles between 1995 and 2016 ([Table 1](#t1-jptm-2019-08-05){ref-type="table"}, [Supplementary Table S1](#SD1-jptm-2019-08-05){ref-type="supplementary-material"}) \[[@b2-jptm-2019-08-05],[@b5-jptm-2019-08-05]-[@b12-jptm-2019-08-05]\].

The average age and sex of concurrent anti-GBM disease and IgA nephropathy in reported cases was 43 years old with a male: female ratio of 1:1.5. Cases were reported in China (n=5), the United States (n=2), Canada (n=1), and Japan (n=1). None of the cases was previously diagnosed as immune complex GN including IgA nephropathy. A recent history of hematuria or proteinuria was shown in 40% of cases and a history of upper respiratory tract infection was present in 20% of cases. None showed symptoms of hemoptysis or pulmonary involvement based on image analysis. Oliguria was seen in 10% of cases. The mean proteinuria, serum Cr levels, and anti-GBM antibody titer (among available cases) were 2.6 g/day, 5.0 mg/dL, and 180 EU/ mL. The ANCA autoantibody was not identified. The percentage of fibrocellular or cellular crescents in renal biopsies was 59%. All cases were treated with steroids and some cases with combined cytotoxic immunosupressive agents, including cyclophosphamide, mycophenolate mofetil, or methotrexate. Plasmapheresis was applied to 30% of cases. More than half (60%) of cases showed improved renal function and dialysis dependence was shown in 30% of cases.

Cui et al. \[[@b2-jptm-2019-08-05]\] compared clinical and laboratory data of patients suffering anti-GBM disease associated with depositions of immune complexes (10 cases) with data from anti-GBM disease alone (37 cases). No significant differences in clinical and pathological findings were observed. In comparison with anti-GBM disease associated with depositions of immune complexes reported by Cui et al. \[[@b2-jptm-2019-08-05]\], this present review of cases with concurrent antiGBM disease and IgA nephropathy showed a tendency of better prognosis. Symptoms of oliguria were reported less commonly in concurrent anti-GBM disease and IgA nephropathy (10%) than in anti-GBM disease with depositions of immune complexes (40%). Percentage of crescent formation in cases of concurrent anti-GBM disease and IgA nephropathy (59%) is less than that in cases of anti-GBM disease with deposition of immune complexes (93.8%). Dialysis independence was more frequent in concurrent anti-GBM disease and IgA nephropathy (60%) than in anti-GBM disease with immune complexes (10%).

The connection between anti-GBM disease and IgA nephropathy is uncertain. IgA nephropathy is the most common immune complex--mediated GN and clinical features vary from asymptomatic hematuria to RPGN \[[@b13-jptm-2019-08-05]\]. Occurrence of anti-GBM disease superimposed on underlying symptomatic IgA nephropathy could be a possible explanation. No cases were confirmed as IgA nephropathy before diagnosis of anti-GBM nephritis in the present review; however, a history of upper respiratory tract infection or microscopic hematuria was noted in some cases. Pathological changes of GBM components triggered by IgA-related immune complex deposition is another hypothesis \[[@b14-jptm-2019-08-05]\]. Anti-GBM antibodies might alter the permeability of GBM to allow circulating immune complex deposition in the mesangium \[[@b2-jptm-2019-08-05]\].

Based on the present review of a limited number of cases, concurrent anti-GBM disease and IgA nephropathy seems to have a better prognosis than anti-GBM disease alone or anti-GBM disease with immune complexes. In order to understand concurrent anti-GBM disease and IgA nephropathy as more than just a simple coincidence of the two diseases, more cases need to be analyzed with an in-depth examination of underlying pathogenic relationships between anti-GBM disease and IgA nephropathy.
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![(A) Light microscopy shows encircling cellular crescents (periodic acid--Schiff staining). Imunofluorescence shows linear deposition of IgG along the glomerular basement membrane (GBM) (B) and granular deposition of IgA in mesangial spaces (C). (D) Electron microscopy shows a diffusely wrinkled GBM and mesangial electron-dense deposition (arrow) (uranyl acetate/lead citrate staining, ×8,000).](jptm-2019-08-05f1){#f1-jptm-2019-08-05}

![Clinical course of the patient. GBM, glomerular basement membrane; PD, prednisolone.](jptm-2019-08-05f2){#f2-jptm-2019-08-05}

###### 

Clinical characteristics of 10 cases (including the present case) of concurrent anti-GBM nephritis and IgA nephropathy in the literature

  Characteristic                                 Percent
  ---------------------------------------------- -------------
  Male:Female ratio                              4:6 (1:1.5)
  Age, mean (range, yr)                          43 (27--60)
  History of upper respiratory tract infection   20
  History of hematuria or proteinuria            40
  Symptoms or signs                              
   Hemoptysis or abnormal chest findings         0
   Oliguria                                      10
   Nephrotic syndrome                            20
  Laboratory findings                            
   Proteinuria, mean (g/day)                     2.6
   Hematuria                                     100
   Creatinine, mean (mg/dL)                      5.0
   Anti-GBM antibody titer, mean (EU/mL)         180
   Percentage of crescents, mean                 59
  Treatment                                      
   Intravenous methyl-PD + Oral-PD               100
   Cyclophosphamide                              60
   Mycophenolate mofetil                         20
   Methotrexate                                  10
   Plasmapheresis                                30
  Prognosis                                      
   Improved                                      60
   Not improved                                  40
   Expired (due to gastrointestinal bleeding)    10
  Dialysis                                       
   Independent                                   60
   Dependent                                     30

GBM, glomerular basement membrane; PD, prednisolone.
